The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Membrane separation processes operate without heating and therefore use less energy than conventional thermal separation processes such as distillation, sublimation, or crystallization. The separation process is purely physical and both fractions (permeate and retentate) can be obtained as useful products. Cold separation using membrane technology is widely used in the food technology, biotechnology and pharmaceutical industries. Furthermore, using membranes enables separations to take place that would be impossible using thermal separation methods. For example, it is impossible to separate the constituents of azeotropic liquids or solutes which form isomorphic crystals by distillation or recrystallization, but such separations can be achieved using membrane technology. Depending on the type of membrane, selective separation of certain individual substances or substance mixtures is possible. Important technical applications include the production of drinking water by reverse osmosis. In waste water treatment, membrane technology is becoming increasingly important. Ultra/microfiltration can be very effective in removing colloids and macromolecules from wastewater. This is needed if wastewater is discharged into sensitive waters especially those designated for contact water sports and recreation. About half of the market is in medical applications such as artificial kidneys to remove toxic substances by hemodialysis and as artificial lung for bubble-free supply of oxygen in the blood.
== Biological function == In animal tissue, BCKDC catalyzes an irreversible step in the catabolism of the branched-chain amino acids L-isoleucine, L-valine, and L-leucine, acting on their deaminated derivatives (L-alpha-keto-beta-methylvalerate, alpha-ketoisovalerate, and alpha-ketoisocaproate, respectively) and converting them to α-Methylbutyryl-CoA, Isobutyryl-CoA and Isovaleryl-CoA respectively. In bacteria, this enzyme participates in the synthesis of branched, long-chain fatty acids. In plants, this enzyme is involved in the synthesis of branched, long-chain hydrocarbons. The overall catabolic reaction catalyzed by the BCKDC is shown in Figure 1.
=== 2017 === On 29 September 2017, BSAT-4a, dedicated for UHDTV programming and was also claimed "the world's first 8K satellite", was launched from the Guiana Space Centre aboard Ariane 5 rocket. BSAT-4a would be used for 2020 Summer Olympics held in Japan. Additionally, in September 2017, Kaleidescape, a manufacturer of home-theater movie players and servers made 4K UHD movies compatible with their movie store, and with their movie players. In December 2017, Qualcomm announced that their Snapdragon 845 chipset and Spectra 280 Image Signal Processor would be the first phone SoC to record video in UHD Premium.
Sources: en.wikipedia.org
=== Mitochondrial function and morphology === Prohibitins are assembled into a ring-like structure with 16–20 alternating Phb1 and Phb2 subunits in the inner mitochondrial membrane. The precise molecular function of the PHB complex is not clear, but a role as chaperone for respiratory chain proteins or as a general structuring scaffold required for optimal mitochondrial morphology and function are suspected. Recently, prohibitins have been demonstrated to be positive, rather than negative, regulators of cell proliferation in both plants and mice.
Histology image: 08601ooa – Histology Learning System at Boston University - "Integument: scalp, transverse" Histology image: 08801ooa – Histology Learning System at Boston University - "Integument: scalp" lesson1 at The Anatomy Lesson by Wesley Norman (Georgetown University) http://www.dartmouth.edu/~humananatomy/figures/chapter_47/47-1.HTM Archived 2016-04-30 at the Wayback Machine
== Structure == Creatinase is a homodimeric enzyme with a calculated molecular mass of approximately 94,000 ± 2,000 Da. Each monomer subunit contains 403 amino-acid residues split between two distinct structural domains. The enzyme was purified and crystallized in 1976 after being extracted from P. putida.
33,000, 25 October 2017 - The SENSEX closed at 33,042.50, for its first close above the 33,000 level. 34,000, 26 December 2017 - The SENSEX closed at 34,010.62, for its first close above the 34,000 level. 35,000, 17 January 2018 - The SENSEX closed at 35,081.82, for its first close above the 35,000 level. 36,000, 23 January 2018 - The SENSEX closed at 36,139.98, for its first close above the 36,000 level. 37,000, 27 July 2018 - The SENSEX on 26 July 2018 crossed the 37,000 mark for the first time during intra-day trading. On 27 July 2018 the index closed above the milestone. 38,000, 9 August 2018 - For the first time SENSEX passed the score of 38,000 during intra-day trading, and then closed at 38,024.37. 39,000, 1 April 2019 – The SENSEX on 1 April 2019 crossed the 39,000 mark for the first time during intra-day trading. 2 April 2019 – The SENSEX closed at 39,056.65, for its first close above the 39,000 level. 40,000, 23 May 2019 – The SENSEX crossed "40,000.100" at 10:45 AM for the first time. (2019 Loksabha (House of the People) Election results were getting published) 41,000, 26 November 2019 – The SENSEX crossed "41,120.28" first time during intraday trading. 42,000, 16 January 2020 - The SENSEX crossed 42,000 mark with an all-time high of 42,059.45 at around 09:47 AM. 45,000, 4 December 2020 - The SENSEX crossed 45,000 mark with an all-time high of 45,033 at around 10:30 AM. 46,000, 9 December 2020 - The SENSEX crossed 46,000 mark with an all-time high of 46,017 at around 1:30 PM.
Sources: en.wikipedia.org
Muslim organizations in the United States were swift to condemn the attacks and called "upon Muslim Americans to come forward with their skills and resources to help alleviate the sufferings of the affected people and their families." These organizations included the Islamic Society of North America, American Muslim Alliance, American Muslim Council, Council on American-Islamic Relations, Islamic Circle of North America, and the Shari'a Scholars Association of North America. Along with monetary donations, many Islamic organizations launched blood drives and provided medical assistance, food, and shelter for victims.
==== Practical uses of polarised T-cell help ==== Polarisation in T-cell help is useful in influencing allergic responses and autoimmune diseases. In autoimmune diseases, the goal is to shift the self-destructive TH1 response (with its associated cytotoxic T cell activity) to a non-destructive TH2 response. This has been successfully applied in predisease priming for the desired type of response in preclinical models and is somewhat successful in shifting the response for an established disease.
Gabapentin, under the brand name Neurontin, was first approved in May 1993 for the treatment of epilepsy in the United Kingdom, and was marketed in the United States in 1994. Subsequently, gabapentin was approved in the United States for the treatment of postherpetic neuralgia in May 2002. A generic version of gabapentin first became available in the United States in 2004. An extended-release formulation of gabapentin for once-daily administration, under the brand name Gralise, was approved in the United States for the treatment of postherpetic neuralgia in January 2011. Pregabalin, under the brand name Lyrica, was approved in Europe in 2004 and was introduced in the United States in September 2005 for the treatment of epilepsy, postherpetic neuralgia, and neuropathic pain associated with diabetic neuropathy. It was subsequently approved for the treatment of fibromyalgia in the United States in June 2007. Pregabalin was also approved for the treatment of generalized anxiety disorder in Europe in 2005, though it has not been approved for this indication in the United States. Gabapentin enacarbil, under the brand name Horizant, was introduced in the United States for the treatment of restless legs syndrome in April 2011 and was approved for the treatment of postherpetic neuralgia in June 2012. Phenibut, marketed under the brand names Anvifen, Fenibut, and Noofen, was introduced in Russia in the 1960s for the treatment of anxiety, insomnia, and a variety of other conditions.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.